Correlations between clinical severity, genotype and muscle pathology in limb girdle muscular dystrophy type 2A

Journal of Medical Genetics

Volumn 44, Issue 10, 2007, Pages 609-614

  Fanin, M ^a   Nardetto, L ^a   Nascimbeni, A C ^a   Tasca, E ^a   Spinazzi, M ^a   Padoan, R ^a   Angelini, C ^a  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN 3;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; GENE MUTATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIMB GIRDLE MUSCULAR DYSTROPHY; MISSENSE MUTATION; MUSCLE BIOPSY; MUSCLE DISEASE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE OF ONSET; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; GENOTYPE; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUSCLES; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUTATION; MUTATION, MISSENSE; VARIATION (GENETICS);

EID: 35348837158     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2007.050328     Document Type: Article

References (33)

1. OMIM. Online Mendelian Inheritance In Man. LGMD2A. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=253600.
2. Fanin M, Nascimbeni AC, Fulisio L, Angelini C. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromusc Disord 2005;15:218-24.
3. Piluso G, Politano L, Aurino S, Fanin M, Ricci E, Ventriglia VM, Belsito A, Totaro A, Saccone V, Topaloglu H, Nascimbeni AC, Fulizio L, Broccolini A, Canki-Klain N, Comi U, Nigra G, Angelini C, Nigra V. The extensive scanning of the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. J Med Genet 2005;42:686-93.
4. Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N, Brenguier L, Devaud C, Pasturaud P, Roudaut C, Hillaire D, Passos-Bueno MR, Zatz M, Tischfield JA, Fardeau M, Jackson CE, Cohen D, Beckmann JS. Mutations in the proteolytic calpain-3 cause limb-girdle muscular dystrophy type 2A. Cell 1995;81:27-40.
5. Sorimachi H, Imajoh-Ohmi S, Emori Y, Kawasaki H, Ohno S, Minami Y, Suzuki K. Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and μ-types: specific expression of tfie mRNA in skeletal muscle. J Biol Chem 1989;264:20106-11.
6. Baghdiguian S, Martin M, Richard I, Pons F, Astier C, Bourg N, Hay RT, Chemaly R, Halaby G, Loiselet J, Anderson LVB, De Munain AL, Fardeau M, Mangeat P, Beckmann JS, Lefranc G. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkBα/NF-κB pathway in LGMD type 2A. Nat Med 1999;5:503-11.
7. Huang J, Forsberg NE. Role of calpain in skeletal-muscle protein degradation. Proc Natl Acad Sci USA 1998;95:12100-5.
8. Poussard S, Duvert M, Balcerzak D, Ramassay S, Brustis JJ, Cottin P, Ducastaing A. Evidence for implication of muscle-specific calpain (p94) in myofibrillar integrity. Cell Growth Differ 1996;7:1461-9.
9. Keira Y, Noguchi S, Minami N, Hayashi YK, Nishino I. Localization of calpain-3 in human skeletal muscle and its alterations in limb-girdle muscular dystrophy 2A muscle. J Biochem 2003;133:659-64.
10. Spencer MJ, Guyon JR, Sorimachi H, Potts A, Richard I, Herasse M, Chamberlain J, Dalkilic I, Kunkel LM, Beckmann JS. Stable expression of calpain-3 from a muscle transgene in-vivo: immature muscle in transgenic mice suggests a role for calpain-3 in muscle maturation. Proc Natl Acad Sci USA 2002;99:8874-9.
11. Richard I, Roudaut C, Saenz A, Pogue R, Grinbergen JEMA, Anderson LVB, Beley C, Cobo AM, De Diego C, Eymard B, Gallano P, Ginjaar HB, Lasa A, Pollitt C, Topaloglu H, Urtizberea JA, De Visser M, Van der Kooi A, Bushby K, Bakker E, Lopez De Munain A, Fardeau M, Beckmann JS. Calpainopathy. A survey of mutations and polymorphisms. Am J Hum Genet 1999;64:1524-40.
12. Saenz A, Leturcq F, Cobo AM, Poza JJ, Ferrer X, Otaegui D, Camano P, Urtasun M, Vilchez J, Gutierrez-Rivas E, Emparanza J, Merlini L, Paisan C, Goicoechea M, Blazquez L, Eymard B, Lochmuller H, Walter M, Bonnemann C, Figarella-Branger D, Kaplan JC, Urtizberea JA, Mart-Masso JF, Lopez De Munain A. LGMD2A: genolype-phenotype correlations based on a large mutational survey on the calpain-3 gene. Brain 2005;128:732-42.
13. Fanin M, Fulizio L, Nascimbeni AC, Spinazzi M, Piluso G, Ventriglia VM, Ruzza G, Siciliano G, Trevisan CP, Politano L, Nigro V, Angelini C. Molecular diagnosis in LGMD2A: mutation analysis or protein testing? Hum Mut 2004;24:52-62.
14. Pollitt C, Anderson LVB, Pogue R, Davison K, Pyle A, Bushby KMD. The phenotype of calpainopathy: diagnosis based on a multidisciplinary approach. Neuromusc Disord 2001;11:287-96.
15. Anderson LVB, Davison K, Moss JA, Richard I, Fardeau M, Tomè FMS, Hubner C, Lasa A, Colomer J, Beckmann J. Characterisation of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb girdle muscular dystrophy type 2A. Am J Pathol 1998;153:1169-79.
16. Fardeau M, Hillaire D, Mignard C, Feingold N, Feingold J, Mignard D, De Ubeda B, Collin H, Tomè FMS, Richard I, Beckmann J. Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996;199:295-308.
17. Krahn M, Bernard R, Pecheux C, Hammouda el H, Eymard B, Lopez de Munain A, Cobo AM, Romero N, Urtizberea A, Leturcq F, Levy N, The Calpain Study Group of the French LGMD Network. Screening of the CAPN3 gene in patients with possible LGMD2A. Clin Genet 2006;69:444-9.
18. De Paula F, Vainzof M, Passos-Bueno MR, De Cassia-Pavnello R, Russo-Mattioli S, Anderson LVB, Nigra V, Zatz M. Clinical variability in calpainopathy: what makes the difference? Eur J Hum Genet 2002;10:825-32.
19. Walton JN, Nattrass FJ. On the classification, natural history and treatment of the myopathies. Brain 1954;77:169-231.
20. Nevin S. Two cases of muscular degeneration occurring in late adult life with a review of the recorded cases of late progressive muscular dystrophy (late progressive myopathy). Q J Med 1936;5:51.
21. Walton JN, Gardner-Medwin D. Muscular dystrophy and myotonias. In: Walton JN, ed. Disorders of voluntary muscle. Edinburgh: Churchill-Livingstone, 1981:481-524.
22. Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. Neuropath Appl Neurobiol 2002;28:461-70.
23. Fanin M, Angelini C. Regeneration in sarcoglycanopathies: expression studies of sarcoglycans and other muscle proteins. J Neurol Sci 1999;165:170-7.
24. Fanin M, Nascimbeni AC, Fulizio L, Trevisan CP, Meznaric-Petrusa M, Angelini C. Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression. Am J Pathol 2003;163:1929-36.
25. In:, Dubowitz V, ed. Muscle biopsy. A practical approach. London: Bailliere Tindall, 1985.
26. Chae J, Minami N, Jin Y, Nagakawa M, Murayama K, Igarashi F, Nonaka I. Calpain-3 gene mutations: genetic and clinico-pathological findings in limb girdle muscular dystrophy. Neuromusc Disord 2001;11:547-55.
27. Hermanova M, Zapletalova E, Sedlackova J, Chrobakova T, Letocha O, Kroupova I, Zamecnik J, Vondracek P, Mazanec R, Marikova T, Vohanka S,
28. Fajkusova L. Analysis of histopathological and molecular pathological findings in Czech LGMD2A patients. Muscle Nerve 2006;33:424-32.
29. Kramerova I, Kudryashova E, Tindball JG, Spencer MJ. Null mutation of calpain-3 (p94) in mice causes abnormal sarcomere formation in-vivo and in-vitro. Hum Molec Genet 2004;13:1373-88.
30. Duguez S, Bartoli M, Richard I. Calpain 3: a key regulator of the sarcomere. FEBS J 2006;273:3427-36.
31. Kramerova I, Kudryashova E, Venkatraman G, Spencer MJ. Calpain 3 participates in sarcomere remodelling by acting upstream of the ubiquitin-proteasome proteolytic pathway. Hum Molec Genet 2005;14:2125-34.
32. Keira Y, Noguchi S, Kurokawa R, Fujita M, Minami N, Hayashi YK, Kato T, Nishino I. Characterization of tabulated fibers in limb girdle muscular dystrophy type 2A by gene expression profiling. Neurosci Res 2007;57:513-21.
33. Bartoli M, Richard I. Calpains in muscle wasting. Intl J Biochem Cell Biol 2005;37:2115-33.